Evidence map›Paper›PMID 37444505›Full record

ArticleCancers2023

The Challenges and Opportunities of the Implementation of Comprehensive Genomic Profiling in Everyday Clinical Practice with Non-Small Cell Lung Cancer: National Results from Croatia.

Dora Čerina, Kristina Krpina, Marko Jakopović, Natalija Dedić Plavetić, Fran Seiwerth, Snježana Tomić, Jasna Radić, Ingrid Belac Lovasić, Ivana Canjko, Marijo Boban and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Dora ČerinaDepartment of Oncology, University Hospital Center Split, 21000 Split, Croatia.
Kristina KrpinaDepartment for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Marko JakopovićDepartment for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-4815-7512
Natalija Dedić PlavetićSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Fran SeiwerthDepartment for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Snježana TomićSchool of Medicine, University of Split, 21000 Split, Croatia.
Jasna RadićDepartment of Oncology and Nuclear Medicine, Division of Medical Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia.
Ingrid Belac LovasićSchool of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
Ivana CanjkoDepartment of Radiotherapy Oncology, University Hospital Center Osijek, 31000 Osijek, Croatia.
Marijo BobanDepartment of Oncology, University Hospital Center Split, 21000 Split, Croatia.
Miroslav SamaržijaDepartment for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, 10000 Zagreb, Croatia.
Eduard VrdoljakDepartment of Oncology, University Hospital Center Split, 21000 Split, Croatia.
University Hospital Centre Zagreb · HRUniversity of Split · HRUniversity of Osijek · HRUniversity of Rijeka · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) has become the best example of precision oncology's impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and most importantly, patients. Consequently, the implementation of the precision oncology concept in medical systems, in order to achieve optimal and proven curative effects in NSCLC, is imperative. In this study, we investigated the development, challenges, and results associated with the implementation of precision oncology in NSCLC on a national level in Croatia. We conducted a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients with metastatic lung cancer, on whose tumors specimen comprehensive genomic profiling (CGP) testing was performed during 2020 and 2021. A total of 48 patients were included in the study. CGP revealed clinically relevant genomic alterations (CRGA) in 37 patients (79%), with a median of 2 (IQR 1-3) CRGA per patient. From the panel of recommended tests,

Indexed as

comprehensive genomic profilingNSCLCprecision medicine

Identifiers

PMID37444505
PMCPMC10340418
OpenAlexW4382722296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.